Leptomeningeal Metastases [LM] Phase 1/2a Dose Escalation Trial using Rhenium (Re-186) obisbemeda{Re-186-Nanoliposome (186RNL)}: Update for Initial Safety, Feasibility and Preliminary Efficacy (SNMMI 2024) - May 8, 2024 - Pres time: Jun 11, 2024; 09:30 AM - 10:45 AM; Location: Exhibit Hall D - Science Pavilion (Convention Center); Screen 44; In-Person Only; "186RNL's unique, single-dose formulation and characteristics, showing increasing SA absorbed doses with dose escalation, has been shown to be safe and well tolerated in patients with LM through 44. 10mCi with consistent quantified CSF tumor-cell reductions and LM clinical improvement. Enrollment continues to determine the recommended phase 2 dose, further safety and preliminary efficacy observations."
Clinical • P1/2 data • CNS Tumor • Melanoma • Oncology • Solid Tumor
|
|
Norman LaFrance; Andrew J. Brenner, Andrew, MD; Michael Youssef, MD; Ande Bao, PhD; Priya Kumthekar; Joel Michalek, PhD; Marc H. Hedrick, MD; William Phillips; Toral R. Patel, MD; Jeffrey S. Weinberg, MD; John R. Floyd, MD, MD; Leonardo Juverdianu; Melissa Moore, PhD
|